Skip to main content

Table 1 Laboratory and treatment characteristics of the study population

From: The atrial uremic cardiomyopathy regression in patients after kidney transplantation – the prospective echocardiographic study

Parameter

Before KTx

Immediately after KTx

3 months after KTx

6 months after KTx

12 months after KTx

36 months after KTx

0 (n = 42)

I (n = 42)

II (n = 42)

III (n = 42)

IV (n = 42)

V (n = 42)

Biochemical markers

 Haemoglobin [g/dl]

12,25 (±3,67)

10,8 (±3,03)

13,3 (±3,51)

13,65 (±3,38)

13,35 (±3,19)

14,1 (±3,14)

 Natrium [mmol/l]

139,0 (±2,71)

139,5 (±2,45)

141,0 (±2,21)

143,0 (± 2,49)

141,0 (±2,33)

142,1 (±2,13)

 Potassium [mmol/l]

4,7 (±1,31)

4,75 (±1,22)

4,45 (±1,19)

4,55 (±1,15)

4,4 (±1,25)

4,4 (±1,09)

 Magnesium [mmol/l]

0,99 (±0,28)

0,73 (±0,31)

0,72 (±0,26)

0,80 (±0,34)

0,82 (±0,30)

0,83 (±0,37)

 Calcium [mmol/l]

2,54 (±0,24)

2,42 (±0,27)

2,55 (±0,35)

2,6 (±0,29)

2,6 (±0,41)

2,52 (±0,32)

 Phosphorus [mmol/l]

1,68 (±0,49)

0,78 (±0,35)

0,84 (±0,40)

0,92 (±0,33)

0,94 (0,42)

0,97 (±0,43)

 Ca x P [mg2/dl2]

52,47 (±13,94)

23,40 (±8,22)

26,56 (±7,17)

29,68 (±7,93)

30,32 (±6,84)

30,33 (±7,35)

 Parathormone [pg/ml]

734,3 (±656,8)

169,0 (±132,0)

130,2 (±102,9)

113,2 (±90,2)

108,0 (±101,2)

97,0 (±88,6)

 Creatinine [mg/dl]

6,54 (±2,21)

1,45 (±0,51)

1,41 (±0,54)

1,38 (±0,48)

1,36 (±0,60)

1,32 (±0,44)

 eGRF [ml/min/1,73m2]

10,9 (±7,6)

55,6 (±22,9)

56,9 (±21,2)

57,5 (±18,8)

58,72 (±18,3)

60,4 (±15,3)

 Urea [mmol/l]

9,74 (±5,72)

8,39 (±4,98)

7,86 (±4,73)

7,64 (±4,88)

7,74 (±4,32)

7,74 (±4,91)

 Total protein [g/l]

75,0 (±14,3)

61,5 (±13,5)

69,0 (±13,9)

70,2 (±13,2)

71,0 (±14,1)

73,0 (±12,9)

 Albumin [g/l]

4,6 (±1,13)

3,9 (±1,09)

4,4 (±1011)

4,43 (±1,17)

4,45 (±1,21)

4,47 (±1,08)

 hs-CRP [mg/l]

2,12 (±2,22)

0,76 (±1,20)

0,7 (±0,93)

0,66 (±1,39)

0,84 (±0,95)

0,74 (±1,08)

 Total cholesterol [mg/dl]

219,0 (±67,2)

218,55 (±44,5)

205,0 (±40,6)

195,3 (±45,6)

195,5 (±50,2)

197,0 (±52,8)

 LDL-cholesterol [mg/dl]

131,0 (±44,15)

128,0 (±39,6)

113,3 (±42,9)

102,5 (±42,6)

110,5 (±38,5)

108,0 (±34,2)

 HDL-cholesterol [mg/dl]

66,1 (±24,55)

53,5 (±21,8)

57,0 (±19,8)

58,9 (±22,4)

53,5 (±18,9)

61,0 (±20,6)

 Triglycerides [mg/dl]

214,3 (±67,64)

201,0 (±60,3)

183,3 (±64,7)

164,5 (±58,4)

153,5 (±55,6)

126,0 (±52,7)

 Glucose [mg/dl]

90,77 (±47,19)

85,2 (±50,5)

95,0 (±44,2)

94,6 (±39,9)

92,0 (±29,2)

88,1 (±32,3)

 Troponin T [μg/l]

0,018 (±0,037)

0,022 (±0,011)

0,014 (±0,021)

0,013 (±0,015)

0,016 (±0,021)

0,014 (±0,024)

 Myoglobin [ng/ml]

183,5 (±171,1)

38,2 (±36,7)

47,5 (±44,2)

46,5 (±39,5)

57,0 (±35,8)

63,5 (±32,4)

 Creatine kinase [U/l]

81,1 (±86,2)

25,5 (±22,4)

54,5 (±32,5)

80,0 (±35,3)

87,2 (±29,4)

93,0 (±37,2)

 Creatine kinase myocardial bound [U/l]

17,4 (±8,12)

11,8 (±7,21)

16,8 (±9,59)

15,0 (±10,24

15,2 (±8,46)

14,1 (±9,81)

Drugs other than immunosuppressants

 ACE-inhibitors/sartans [n (%)]

0 (%)

0

0

0

0

0

 Calcium blockers [n (%)]

40 (95,2%)

40 (95,2%

38 (90,4%)

38 (90,4%)

36 (85,7%)

36 (85,7%)

 Beta-blockers [n (%)]

23 (54,8%)

25 (59,5%)

26 (61,9%)

24 (57,1%)

26 (61,9%)

27 (64,2%)

 Alfa-blockers [n (%)]

5 (11,9%)

6 (14,2%)

6 (14,2%)

7 (16,6%)

5 (11,9%)

5 (11,9%)

 Clonidine [n (%)]

31 (73,8%)

31 (73,8%)

30 (71,4%)

26 (61,9%)

24 (57,1%)

20 (47,6%)

 Diuretic [n (%)]

40 (95,2%)

30 (71,4%)

18 (42,8%)

10 (23,8%)

6 (14,2%)

5 (11,9%)

 Fibrats [n (%)]

5 (11,9%)

8 (19,0%)

10 (23,8%)

10 (23,8%)

10 (23,8%)

12 (28,5%)

 Statins [n (%)]

3 (7,1%)

10 (23,8%)

17 (40,4%)

22 (52,3%)

22 (52,3%)

23 (54,7%)

Immunosuppressive drugs

 Cyclosporine [n (%)]

21 (50,0%)

21 (50,0%)

20 (47,6%)

18 (42,9%)

17 (40,5%)

12 (28,6%)

 Tacrolimus [n (%)]

21 (50,0%)

21 (50,0%)

22 (52,4%)

24 (57,1%)

25 (59,5%)

30 (71,4%)

 Mycophenolate mofetil [n (%)]

42 (100%)

42 (100%)

42 (100%)

42 (100%)

42 (100%)

42 (100%)

 Prednisone [n (%)]

42 (100%)

42 (100%)

42 (100%)

42 (100%)

42 (100%)

42 (100%)